Ansuvimab

Ansuvimab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	Zaire ebolavirus
Clinical data
Trade names	Ebanga
Other names	Ansuvimab-zykl, mAb114
License data	US DailyMed: Ansuvimab;
Routes of; administration	Intravenous
Drug class	Monoclonal antibody
ATC code	J06BD04 (WHO) ;
Legal status
Legal status	US: ℞-only;
Identifiers
CAS Number	2375952-29-5;
DrugBank	DB16385;
UNII	TG8IQ19NG2;
KEGG	D11875;
Chemical and physical data
Formula	C6368H9924N1724O1994S44
Molar mass	143950.15 g·mol−1

Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.^[1]^[2]

The most common symptoms include fever, tachycardia (fast heart rate), diarrhea, vomiting, hypotension (low blood pressure), tachypnea (fast breathing) and chills; however, these are also common symptoms of Ebolavirus infection.^[1]

Ansuvimab was approved for medical use in the United States in December 2020.^[1]^[2]^[3] It is on the World Health Organization's List of Essential Medicines.^[4]

^ ^a ^b ^c ^d "FDA Approves Treatment for Ebola Virus". U.S. Food and Drug Administration. 21 December 2020. Retrieved 23 December 2020. This article incorporates text from this source, which is in the public domain.
^ ^a ^b "Ridgeback Biotherapeutics LP Announces the Approval of Ebanga for Ebola" (Press release). Ridgeback Biotherapeutics LP. 22 December 2020. Retrieved 23 December 2020 – via Business Wire.
^ "Drug Trials Snapshot: Ebanga". U.S. Food and Drug Administration (FDA). 21 December 2020. Retrieved 13 January 2021. This article incorporates text from this source, which is in the public domain.
^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[FDA_Ebanga-1] "FDA Approves Treatment for Ebola Virus". U.S. Food and Drug Administration. 21 December 2020. Retrieved 23 December 2020. This article incorporates text from this source, which is in the public domain.

[Ridgeback_PR-2] "Ridgeback Biotherapeutics LP Announces the Approval of Ebanga for Ebola" (Press release). Ridgeback Biotherapeutics LP. 22 December 2020. Retrieved 23 December 2020 – via Business Wire.

[FDA_snapshot-3] "Drug Trials Snapshot: Ebanga". U.S. Food and Drug Administration (FDA). 21 December 2020. Retrieved 13 January 2021. This article incorporates text from this source, which is in the public domain.

[WHO23rd-4] World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.

[1]

[2]

[3]

[4]